BR112019002730A2 - acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa - Google Patents

acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa

Info

Publication number
BR112019002730A2
BR112019002730A2 BR112019002730-0A BR112019002730A BR112019002730A2 BR 112019002730 A2 BR112019002730 A2 BR 112019002730A2 BR 112019002730 A BR112019002730 A BR 112019002730A BR 112019002730 A2 BR112019002730 A2 BR 112019002730A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salt
treating
acetyl leucine
neurodegenative disease
Prior art date
Application number
BR112019002730-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019002730(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of BR112019002730A2 publication Critical patent/BR112019002730A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019002730-0A 2016-08-11 2017-08-11 acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa BR112019002730A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB1613829.9 2016-08-11
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB1702551.1 2017-02-16
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB1705766.2 2017-04-10
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB1706867.7 2017-04-28
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
BR112019002730A2 true BR112019002730A2 (pt) 2019-05-14

Family

ID=59859424

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002730-0A BR112019002730A2 (pt) 2016-08-11 2017-08-11 acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa

Country Status (29)

Country Link
US (3) US12144792B2 (https=)
EP (3) EP4467195A3 (https=)
JP (3) JP6957602B2 (https=)
KR (4) KR20250042197A (https=)
CN (4) CN109789114A (https=)
AU (2) AU2017308865B2 (https=)
BR (1) BR112019002730A2 (https=)
CA (1) CA3033564A1 (https=)
CY (1) CY1121930T1 (https=)
DK (1) DK3416631T3 (https=)
ES (1) ES2733677T3 (https=)
HR (1) HRP20191055T1 (https=)
HU (1) HUE045043T2 (https=)
IL (3) IL310799A (https=)
LT (1) LT3416631T (https=)
MA (2) MA47521A (https=)
MD (1) MD3416631T2 (https=)
ME (1) ME03454B (https=)
MX (3) MX383499B (https=)
NZ (2) NZ750421A (https=)
PL (1) PL3416631T3 (https=)
PT (1) PT3416631T (https=)
RS (1) RS59048B1 (https=)
RU (1) RU2756519C2 (https=)
SG (1) SG11201901063SA (https=)
SI (1) SI3416631T1 (https=)
SM (1) SMT201900370T1 (https=)
TN (1) TN2019000033A1 (https=)
WO (1) WO2018029658A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
WO2016210133A1 (en) 2015-06-24 2016-12-29 The Regents Of The Universtiy Of Michigan Histotripsy therapy systems and methods for the treatment of brain tissue
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
LT3697399T (lt) * 2017-10-18 2026-01-12 Intrabio Ltd Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
JP7337081B2 (ja) * 2018-02-15 2023-09-01 イントラバイオ リミティド レストレスレッグズ症候群を治療するための治療薬
JP2022510654A (ja) 2018-11-28 2022-01-27 ヒストソニックス，インコーポレーテッド 組織破砕システムおよび方法
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
WO2020178721A1 (en) 2019-03-02 2020-09-10 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
US20220346699A1 (en) * 2019-09-17 2022-11-03 Hoffmann-La Roche Inc. Improvements in Personalized Healthcare for Patients with Movement Disorders
US20230051742A1 (en) * 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
JP2023526517A (ja) * 2020-05-22 2023-06-21 イントラビオ エルティーディー 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
EP4608504A1 (en) 2022-10-28 2025-09-03 Histosonics, Inc. Histotripsy systems and methods
KR20260003742A (ko) 2023-04-20 2026-01-07 히스토소닉스, 인크. 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
EP2932958A1 (en) 2007-02-22 2015-10-21 Beiersdorf AG Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
AU2014342624A1 (en) * 2013-10-28 2016-06-02 Naurex, Inc. NMDA receptor modulators and prodrugs, salts, and uses thereof
US10905670B2 (en) 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases

Also Published As

Publication number Publication date
CN109789114A (zh) 2019-05-21
KR102785448B1 (ko) 2025-03-21
MA47521A (fr) 2021-04-21
EP4467195A2 (en) 2024-11-27
WO2018029658A1 (en) 2018-02-15
RU2756519C2 (ru) 2021-10-01
PT3416631T (pt) 2019-07-11
MA43828B1 (fr) 2019-09-30
MA43828A (fr) 2018-12-26
HRP20191055T1 (hr) 2019-09-06
RS59048B1 (sr) 2019-08-30
MX2024004439A (es) 2025-11-03
CA3033564A1 (en) 2018-02-15
MX2019001575A (es) 2019-08-01
IL264641A (en) 2019-04-30
JP2023175762A (ja) 2023-12-12
CN116459244A (zh) 2023-07-21
SMT201900370T1 (it) 2019-09-09
AU2025202077A1 (en) 2025-04-10
CY1121930T1 (el) 2020-10-14
ES2733677T3 (es) 2019-12-02
NZ790893A (en) 2026-03-27
JP2022003085A (ja) 2022-01-11
EP3416631B1 (en) 2019-05-15
RU2019106506A3 (https=) 2020-10-29
KR20220093385A (ko) 2022-07-05
AU2017308865A1 (en) 2019-02-21
ME03454B (me) 2020-01-20
SI3416631T1 (sl) 2019-09-30
JP2019524822A (ja) 2019-09-05
IL264641B1 (en) 2024-03-01
IL310801A (en) 2024-04-01
SG11201901063SA (en) 2019-03-28
KR102413756B1 (ko) 2022-06-27
PL3416631T3 (pl) 2019-11-29
US20230210799A1 (en) 2023-07-06
US20200179320A1 (en) 2020-06-11
CN116492328A (zh) 2023-07-28
DK3416631T3 (da) 2019-07-15
LT3416631T (lt) 2019-08-26
EP3583940A1 (en) 2019-12-25
HUE045043T2 (hu) 2019-12-30
CN121081445A (zh) 2025-12-09
KR20250042197A (ko) 2025-03-26
IL310799A (en) 2024-04-01
MD3416631T2 (ro) 2019-09-30
AU2023202121B2 (en) 2025-01-23
KR20240068761A (ko) 2024-05-17
RU2021128045A (ru) 2021-11-16
KR20190039227A (ko) 2019-04-10
US20240189267A1 (en) 2024-06-13
IL264641B2 (en) 2024-07-01
NZ750421A (en) 2026-03-27
JP6957602B2 (ja) 2021-11-02
MX383499B (es) 2025-03-14
AU2017308865B2 (en) 2023-04-13
JP7833272B2 (ja) 2026-03-19
EP3416631A1 (en) 2018-12-26
US12144792B2 (en) 2024-11-19
AU2023202121A1 (en) 2023-05-04
MX2021006901A (es) 2021-07-07
RU2019106506A (ru) 2020-09-17
TN2019000033A1 (fr) 2020-07-15
EP4467195A3 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR101740A1 (es) Terapia de combinación y composiciones
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX392677B (es) Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
BR112022003719A2 (pt) Métodos para o tratamento de hiperfenilalaninemia
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
BR112017007863A2 (pt) composição para o tratamento de condições envolvendo dor muscular
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]